Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-LECT2
- Development stage
- Preclinical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
Ad-LECT2 is an adenoviral gene therapy vector designed to deliver and overexpress the Leukocyte cell-derived chemotaxin 2 (LECT2) protein, which functions as a tumor suppressor in hepatocellular carcinoma (HCC). LECT2 expression is frequently downregulated in HCC, correlating with poor prognosis and advanced disease stages. By restoring LECT2 levels, Ad-LECT2 suppresses the hepatocyte growth factor (HGF)/c-MET signaling axis, subsequently inhibiting the β-catenin pathway. This molecular intervention leads to the suppression of cancer stem cell (CSC) properties, epithelial-mesenchymal transition (EMT), and neovascularization, while inducing apoptosis in tumor cells. Preclinical evidence suggests that Ad-LECT2 can effectively reduce tumor growth and invasiveness, offering a potential therapeutic strategy for HCC.
- Other names
- adenovirus encoding LECT2
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on Ad-LECT2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-LECT2.